Risk factors for multiple sclerosis and associations with anti-EBV antibody titers

Clinical Immunology

Volumn 158, Issue 1, 2015, Pages 59-66

  Mouhieddine, Tarek H ^a   Darwish, Hala ^a   Fawaz, Lama ^a   Yamout, Bassem ^a   Tamim, Hani ^a   Khoury, Samia J ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Epstein Barr virus; Multiple sclerosis; Risk factors

Indexed keywords

ANTIBODY; EPSTEIN BARR VIRUS ANTIBODY; GLATIRAMER; INTERFERON; METHYLPREDNISOLONE; NATALIZUMAB; UNCLASSIFIED DRUG; VITAMIN D; 25-HYDROXYVITAMIN D; CAPSID PROTEIN; EPSTEIN BARR VIRUS ANTIGEN; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; LEBANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; AGE; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; LEBANON; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OVERWEIGHT; RISK FACTOR; SEX DIFFERENCE; VITAMIN D DEFICIENCY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; CAPSID PROTEINS; CASE-CONTROL STUDIES; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LEBANON; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OVERWEIGHT; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84928342558     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.03.011     Document Type: Article

References (46)

1. Koch-Henriksen N., Sorensen P.S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. May 2010, 9(5):520-532.
2. Almohmeed Y.H., Avenell A., Aucott L., Vickers M.A. Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLoS ONE 2013, 8(4):e61110.
3. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA Dec 20 2006, 296(23):2832-2838.
4. Baarnhielm M., Hedstrom A.K., Kockum I., et al. Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. Eur. J. Neurol. Jul 2012, 19(7):955-962.
5. Hedstrom A.K., Baarnhielm M., Olsson T., Alfredsson L. Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. Mult. Scler. Jul 2011, 17(7):788-793.
6. O'Gorman C., Broadley S.A. Smoking and multiple sclerosis: evidence for latitudinal and temporal variation. J. Neurol. Sep 2014, 261(9):1677-1683.
7. Handel A.E., Williamson A.J., Disanto G., Dobson R., Giovannoni G., Ramagopalan S.V. Smoking and multiple sclerosis: an updated meta-analysis. PLoS ONE 2011, 6(1):e16149.
8. Munger K.L., Bentzen J., Laursen B., et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult. Scler. Sep 2013, 19(10):1323-1329.
9. Gianfrancesco M.A., Acuna B., Shen L., et al. Obesity during childhood and adolescence increases susceptibility to multiple sclerosis after accounting for established genetic and environmental risk factors. Obes. Res. Clin. Pract. Sep-Oct 2014, 8(5):e435-e447.
10. Hedstrom A.K., Lima Bomfim I., Barcellos L., et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 11 2014, 82(10):865-872.
11. Kavak K.S., Teter B.E., Hagemeier J., Zakalik K., Weinstock-Guttman B. Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Mult. Scler. 2014.
12. Nolan D., Castley A., Tschochner M., et al. Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk. Neurology 2012, 79(6):538-546.
13. Lincoln M.R., Montpetit A., Cader M.Z., et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat. Genet. 2005, 37(10):1108-1112.
14. Yamout B., Estaitieh N., Mahfouz R., Karaky N., Jaber F., Daher R. Vitamin D receptor polymorphisms and HLA-class II genotypes among Lebanese with multiple sclerosis - a pilot study. Mult. Scler. Relat. Disord. 2014, 3(6):759.
15. Roschewski M., Wilson W.H. EBV-associated lymphomas in adults. Best Pract. Res. Clin. Haematol. 2012, 25(1):75-89.
16. Rea T.D., Ashley R.L., Russo J.E., Buchwald D.S. A systematic study of Epstein-Barr virus serologic assays following acute infection. Am. J. Clin. Pathol. Jan 2002, 117(1):156-161.
17. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 2007, 61(4):288-299.
18. Sundstrom P., Juto P., Wadell G., et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004, 62(12):2277-2282.
19. Munger K.L., Levin L.I., O'Reilly E.J., Falk K.I., Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult. Scler. 2011, 17(10):1185-1193.
20. Santiago O., Gutierrez J., Sorlozano A., de Dios Luna J., Villegas E., Fernandez O. Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. Eur. J. Clin. Microbiol. Infect. Dis. 2010, 29(7):857-866.
21. Simpson S., Taylor B., Burrows J., et al. EBV & HHV6 reactivation is infrequent and not associated with MS clinical course. Acta Neurol. Scand. 2014, 130(5):328-337.
22. Castellazzi M., Tamborino C., Cani A., et al. Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. Mult. Scler. 2010, 16(7):883-887.
23. Farrell R.A., Antony D., Wall G.R., et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009, 73(1):32-38.
24. Ingram G., Bugert J.J., Loveless S., Robertson N.P. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur. J. Neurol. 2010, 17(11):1386-1389.
25. Kvistad S., Myhr K.M., Holmoy T., et al. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Mult. Scler. 2014, 20(14):1833-1840.
26. Decard B.F., von Ahsen N., Grunwald T., et al. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2012, 83(12):1170-1173.
27. Tizaoui K., Kaabachi W., Hamzaoui A., Hamzaoui K. Association between vitamin D receptor polymorphisms and multiple sclerosis: systematic review and meta-analysis of case-control studies. Cell. Mol. Immunol. 2015, 12:243-252.
28. Ascherio A., Munger K.L., White R., et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014, 71(3):306-314.
29. Munger K.L., Kochert K., Simon K.C., et al. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Ann. Clin. Transl. Neurol. 2014, 1(8):605-617.
30. Lysandropoulos A.P., Jaquiery E., Jilek S., Pantaleo G., Schluep M., Du Pasquier R.A. Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. J. Neuroimmunol. 2011, 233(1-2):240-244.
31. Ramien C., Pachnio A., Sisay S., et al. Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort. Mult. Scler. 2014, 20(6):751-753.
32. Lossius A., Vartdal F., Holmoy T. Vitamin D sensitive EBNA-1 specific T cells in the cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 2011, 240-241:87-96.
33. Simon K.C., van der Mei I.A., Munger K.L., et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 27 2010, 74(17):1365-1371.
34. Salzer J., Stenlund H., Sundstrom P. The interaction between smoking and Epstein-Barr virus as multiple sclerosis risk factors may depend on age. Mult. Scler. 2014, 20(6):747-750.
35. Nielsen T.R., Pedersen M., Rostgaard K., Frisch M., Hjalgrim H. Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. Mult. Scler. Apr 2007, 13(3):420-423.
36. Sundqvist E., Sundstrom P., Linden M., et al. Lack of replication of interaction between EBNA1 IgG and smoking in risk for multiple sclerosis. Neurology Sep 25 2012, 79(13):1363-1368.
37. Hoteit M., Al-Shaar L., Yazbeck C., Bou Sleiman M., Ghalayini T., Fuleihan Gel H. Hypovitaminosis D in a sunny country: time trends, predictors, and implications for practice guidelines. Metabolism Jul 2014, 63(7):968-978.
38. Daher N., Saleh R., Jaroudi E., et al. Comparison of carcinogen, carbon monoxide, and ultrafine particle emissions from narghile waterpipe and cigarette smoking: sidestream smoke measurements and assessment of second-hand smoke emission factors. Atmos. Environ. Jan 1 2010, 44(1):8-14.
39. Cohen J.I. Epstein-Barr virus infection. N. Engl. J. Med. Aug 17 2000, 343(7):481-492.
40. de Ory F., Guisasola M.E., Sanz J.C., Garcia-Bermejo I. Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections. Clin. Vaccine Immunol. Mar 2011, 18(3):444-448.
41. Corrales I., Gimenez E., Navarro D. Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method. Clin. Vaccine Immunol. May 2014, 21(5):684-688.
42. Ascherio A., Munger K.L., Lennette E.T., et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA Dec 26 2001, 286(24):3083-3088.
43. Pohl D., Krone B., Rostasy K., et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology Dec 12 2006, 67(11):2063-2065.
44. Larsen P.D., Bloomer L.C., Bray P.F. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology Mar 1985, 35(3):435-438.
45. Ghadirian P., Dadgostar B., Azani R., Maisonneuve P. A case-control study of the association between socio-demographic, lifestyle and medical history factors and multiple sclerosis. Can. J. Public Health 2001, 92(4):281-285.
46. Compston A., Coles A. Multiple sclerosis. Lancet Oct 25 2008, 372(9648):1502-1517.